1,365 results match your criteria Melanoma Ciliary Body


Treatment of uncontrolled intraocular pressure secondary to uveal melanoma status post plaque radiotherapy with ab interno XEN gel stent implantation.

Am J Ophthalmol Case Rep 2022 Sep 16;27:101610. Epub 2022 Jun 16.

Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, 608 Stanton L Young Blvd, Oklahoma City, OK, 73104, Oklahoma, USA.

Purpose: To report treatment of uncontrolled intraocular pressure in a patient with uveal melanoma status post plaque radiotherapy with ab interno XEN gel stent implantation.

Observations: A 21-year-old female with a history of iris and ciliary body melanoma underwent treatment with plaque radiotherapy with subsequent elevation of intraocular pressure refractory to maximum medical therapy. In order to control the pressure, ab interno XEN gel stent implantation with mitomycin C was recommended. Read More

View Article and Full-Text PDF
September 2022

Underlying Ciliary Body Uveal Melanoma in a Patient with Chronic Lymphocytic Leukemia Presenting for Hyphema.

Diagnostics (Basel) 2022 May 25;12(6). Epub 2022 May 25.

Clinical Department of Ophthalmology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.

(1) Background: Ciliary body uveal melanoma is a rare subtype of uveal melanoma which comprises 3-5% of melanomas, an immunogenic cancer, and can present multifaceted initial clinical manifestations, masquerading as various ocular pathologies. Chronic lymphocytic leukemia (CLL) presents immunodeficiency and risk for the development of a secondary malignancy, with Bruton's tyrosine kinase inhibitor treatment having a mutagenic effect and a secondary anti-platelet aggregation effect. We present the case of a 65-year-old patient undergoing treatment for CLL with ibrutinib who presented with recurrent hyphema that masked an underlying, inferiorly situated, ciliary body uveal melanoma; (2) Methods: Retrospective case review; (3) Results: An ophthalmological examination together with imaging via mode B ultrasound and contrast-enhanced magnetic resonance imaging resulted in the clinical and imagistic diagnosis of a ciliary body uveal melanoma. Read More

View Article and Full-Text PDF

A Novel and Easy-to-Promote Prognostic Model for Patients With Uveal Melanoma.

Front Oncol 2022 2;12:879394. Epub 2022 Jun 2.

Department of Ophthalmology, Eye & Ear, Nose, and Throat (ENT) Hospital of Fudan University, Shanghai, China.

Purpose: To establish an easy and widely applicable prognostic prediction model for uveal melanoma (UM) based on a Chinese population.

Patients And Methods: A total of 295 consecutive cases treated at the Eye & ENT Hospital of Fudan University were included as the primary cohort, and 256 cases were included in the validation cohorts from two external Caucasian databases. Clinicopathological data were collected retrospectively, and nomogram models were formulated based on multivariable analysis. Read More

View Article and Full-Text PDF

Case Report: - and Mutations in an Aggressive Case of Relapsing Uveal Ring Melanoma.

Front Oncol 2022 25;12:873252. Epub 2022 May 25.

Department of Ophthalmology, University Hospital Schleswig-Holstein, University of Lübeck, Lübeck, Germany.

The molecular mechanisms for uveal ring melanoma are still unclear until today. In this case report, we describe a patient with a malignant uveal melanoma with exudative retinal detachment that had been treated with plaque brachytherapy, resulting in successful tumor regression. After 1 year, a ring-shaped recurrence with extraocular extension appeared, and the eye required enucleation. Read More

View Article and Full-Text PDF

Potential of Aqueous Humor as a Liquid Biopsy for Uveal Melanoma.

Int J Mol Sci 2022 Jun 2;23(11). Epub 2022 Jun 2.

The Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.

Tumor biopsy can identify prognostic biomarkers for metastatic uveal melanoma (UM), however aqueous humor (AH) liquid biopsy may serve as an adjunct. This study investigated whether the AH of UM eyes has sufficient circulating tumor DNA (ctDNA) to perform genetic analysis. This is a case series of 37 AH samples, taken before or after radiation, and one tumor wash sample, from 12 choroidal and 8 ciliary body (CB) melanoma eyes. Read More

View Article and Full-Text PDF

Trans-Scleral Cyclophotocoagulation in Refractory Pigment Dispersion-Like Glaucoma Secondary to Ciliary Body Melanoma.

J Curr Ophthalmol 2022 Jan-Mar;34(1):118-120. Epub 2022 Apr 16.

Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.

Purpose: To report a case of ciliary body melanoma with acute high intraocular pressure (IOP) due to pigment dispersion, treated by limited trans-scleral cyclophotocoagulation (TSCPC) and plaque radiotherapy.

Methods: A 33-year-old woman was referred to clinic with acute ocular pain and decreased visual acuity from 1 week before presentation. The IOP was 55 mmHg accompanied by red eye, perilimbal injection, mild corneal edema (stromal and epithelial), scattered pigment dust on central corneal endothelium, 4 anterior chamber pigments, and pigmented cells. Read More

View Article and Full-Text PDF

Necrosis of uveal melanoma post-COVID-19 vaccination.

Indian J Ophthalmol 2022 05;70(5):1837-1840

Department of Ophthalmology, National University Hospital, National University of Singapore, Singapore.

A 49-year-old Indian male presented with rapidly progressive vision loss 1 day after receiving the second dose of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine (Pfizer-BioNTech, NY, USA). The eye had secondary angle closure glaucoma, bullous retinal detachment, and massive intraocular hemorrhage. Ultrasound showed an ill-defined subretinal mass with moderate internal reflectivity. Read More

View Article and Full-Text PDF

Surgical Approach in Intraocular Tumors

Turk J Ophthalmol 2022 04;52(2):125-138

Ankara University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey

Surgery in intraocular tumors is done for excision/biopsy and the management of complications secondary to the treatment of these tumors. Excision/biopsy of intraocular tumors can be done via fine-needle aspiration biopsy (FNAB), transretinal biopsy (TRB), partial lamellar sclerouvectomy (PLSU), and endoresection. FNAB, TRB, and PLSU can be used in tumors that cannot be diagnosed by clinical examination and other ancillary testing methods. Read More

View Article and Full-Text PDF

Dynamic observation: Immune-privileged microenvironment limited the effectiveness of immunotherapy in an intraocular metastasis mouse model.

Ophthalmic Res 2022 Apr 8. Epub 2022 Apr 8.

Introduction: Intraocular metastasis (IM) occurred in approximately 8-10% of patients with metastatic malignancy, for whom oncological immunotherapies showed poor visual potential. However, the mechanism for that inefficiency remains unclear and requires further exploration.

Methods: we established a novel mouse model of intraocular metastasis by intracarotid injection of cutaneous melanoma cells. Read More

View Article and Full-Text PDF

Surgical Resection of Intraocular Tumors (Partial Transscleral Sclerouvectomy Combined With Mircoinvasive Vitrectomy and Reconstruction of the Eyeball) in Asian Patients: Twenty-Five Years Results.

Front Oncol 2022 15;12:768635. Epub 2022 Mar 15.

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Medical Artificial Intelligence Research and Verification Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Objective: To describe the outcome of intraocular tumor resection by partial transscleral sclerouvectomy (PTSU) combined with micro-invasive vitrectomy and reconstruction of the eyeball (MVRE) in Asian patients.

Design Methods And Participants: This retrospective, interventional cohort study included 366 patients who underwent PTSU combined with MVRE for intraocular tumors both in adult and pediatric age groups. The medical records of these patients were reviewed for clinical, operative, and histopathological features. Read More

View Article and Full-Text PDF

Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas.

J Clin Med 2022 Mar 15;11(6). Epub 2022 Mar 15.

Department of Radio Physics, Virgen Macarena University Hospital, 41009 Seville, Spain.

Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. Read More

View Article and Full-Text PDF

A Case of Non-Irradiated Balloon Cell Melanoma of the Choroid: Expanding the Morphological Spectrum of Primary Uveal Melanomas.

Diagnostics (Basel) 2022 Mar 5;12(3). Epub 2022 Mar 5.

Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy.

Uveal melanoma (UM) is the most common primary intraocular tumor in adults and usually has a very poor prognosis. Histologically, UMs have been classified in epithelioid cell type, spindle cell type, and mixed cell type. Balloon cells are large pale cells that contain small, hyperchromatic, central nuclei with vesiculated, clear, and lipid-rich cytoplasm. Read More

View Article and Full-Text PDF

Metastatic tumours to the eye. Review of metastasis to the iris, ciliary body, choroid, retina, optic disc, vitreous, and/or lens capsule.

Eye (Lond) 2022 Mar 19. Epub 2022 Mar 19.

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Metastasis to the eye can involve the choroid (90%), ciliary body (2%), iris (8%), and retina, optic disc, vitreous, and/or lens capsule (<1-4%). The mean number of uveal metastasis per eye (1.7), mean tumour base (11. Read More

View Article and Full-Text PDF

The long-term prognosis of patients with untreated primary uveal melanoma: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2022 Apr 15;172:103652. Epub 2022 Mar 15.

Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Tomtebodavägen 18A, plan 5, 171 77 Stockholm, Sweden; Department of Pathology, Västmanland Hospital Västerås, Västerås, Sweden.

Purpose: To examine patient survival in untreated primary uveal melanoma.

Methods: Systematic review and meta-analysis.

Results: Seven studies with a total of 19 patients were included. Read More

View Article and Full-Text PDF

Metastatic neuroendocrine tumors mimicking as primary ocular disease.

Am J Ophthalmol Case Rep 2022 Jun 15;26:101425. Epub 2022 Feb 15.

Los Angeles County + University of Southern California Medical Center, Department of Ophthalmology, 2051 Marengo St, Los Angeles, CA, 90033, USA.

Purpose: To report two cases of metastatic neuroendocrine tumors masquerading as primary ocular disease.

Observations: Case 1 is a 38-year-old man who was referred with subacute onset diplopia and fluctuating ptosis suggestive of myasthenia gravis. Case 2 is a 21-year-old man who presented with blurry vision and was found to have a pigmented ciliary body mass and retinal detachment suggestive of uveal melanoma. Read More

View Article and Full-Text PDF

Technical note: Impact of beam properties for uveal melanoma proton therapy-An in silico planning study.

Med Phys 2022 May 8;49(5):3481-3488. Epub 2022 Mar 8.

Charité-Universitätsmedizin Berlin, Department of Ophthalmology, Berlin, Germany.

Purpose: To evaluate the impact of beam quality in terms of distal fall-off (DFO, 90%-10%) and lateral penumbra (LP, 80%-20%) of single beam ocular proton therapy (OPT) and to derive resulting ideal requirements for future systems.

Methods: Nine different beam models with DFO varying between 1 and 4 mm and LP between 1 and 4 mm were created. Beam models were incorporated into the RayStation with RayOcular treatment planning system version 10 B (RaySearch Laboratories, Stockholm, Sweden). Read More

View Article and Full-Text PDF

Feline Uveal Melanoma Review: Our Current Understanding and Recent Research Advances.

Vet Sci 2022 Jan 26;9(2). Epub 2022 Jan 26.

The Ophthalmology Department, The University of Edinburgh Hospital for Small Animals (HfSA), Royal (Dick) School of Veterinary Studies (R(D)SVS), Easter Bush Campus, Midlothian EH25 9RG, UK.

Melanocytic neoplasia is the most common form of ocular tumour in cats, accounting for 67% of cases in an analysis of 2614 cases of primary ocular neoplasia. Feline diffuse iris melanoma (FDIM) is by far the most common form of ocular melanocytic neoplasia, with limbal melanomas and atypical melanoma (melanoma affecting the choroid or ciliary body) infrequently recognised. Early lesions begin as flat areas of pigmentation of the iris, known as iris melanosis. Read More

View Article and Full-Text PDF
January 2022

The unfolded protein response and the biology of uveal melanoma.

Biochimie 2022 Jun 29;197:9-18. Epub 2022 Jan 29.

Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia. Electronic address:

Uveal melanoma (UM) is a highly metastatic ocular cancer that arises from the melanocytes of the uveal tract (the choroid, ciliary body and iris). Despite a growing understanding of UM biology, effective systemic treatments are currently lacking and the cancer has an extremely poor prognosis. Therefore, identifying novel agents that act by new tumorigenic mechanisms in UM is essential to address this unmet clinical need. Read More

View Article and Full-Text PDF

Uveal Melanoma and Paraneoplastic Perivascular Dermal Melanocytic Proliferation in the Setting of Bilateral Diffuse Uveal Melanocytic Proliferation: The Potential Role of the Hepatocyte Growth Factor/c-Met Axis in Their Pathogenesis.

Ocul Oncol Pathol 2021 Dec 26;7(6):418-427. Epub 2021 Aug 26.

Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom.

Two patients, with non-small cell lung carcinoma treated with pembrolizumab, developed bilateral diffuse uveal melanocytic proliferation (BDUMP) with interesting histopathological features. The first patient developed a right ciliary body mass concurrently with BDUMP. The globe was enucleated. Read More

View Article and Full-Text PDF
December 2021

Iris melanoma with ciliary body infiltration presenting as a presumed chronic unilateral inflammatory glaucoma. The challenges of iris tumor biopsy assessment.

Pol J Pathol 2021 ;72(3):267-271

Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland.

Uveal melanoma is the most common primary malignancy of the eye in adults. It may involve the choroid and ciliary body, and in only 2-3% of cases it involves the iris. We present a case of a 56-year-old patient with a 6-year history of unilateral, inflammatory, refractory glaucoma of the right eye. Read More

View Article and Full-Text PDF
January 2022

New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.

Cancers (Basel) 2021 Dec 28;14(1). Epub 2021 Dec 28.

Small Animal Magnetic Resonance Imaging Laboratory, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.

Uveal melanoma is the most common intraocular malignancy and arises from melanocytes in the choroid, ciliary body, or iris. The current eye-sparing treatment options include surgical treatment, plaque brachytherapy, proton beam radiotherapy, stereotactic photon radiotherapy, or photodynamic therapy. However, the efficacy of these methods is still unsatisfactory. Read More

View Article and Full-Text PDF
December 2021

Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Cancers (Basel) 2021 Dec 25;14(1). Epub 2021 Dec 25.

Laboratory of Clinical and Experimental Pathology, Université Côte d'Azur, Pasteur Hospital, Centre Hospitalier Universitaire de Nice, Biobank BB-0033-00025, 06000 Nice, France.

Uveal melanoma (UM) is the most common malignant intraocular tumour in the adult population. It is a rare cancer with an incidence of nearly five cases per million inhabitants per year, which develops from the uncontrolled proliferation of melanocytes in the choroid (≈90%), ciliary body (≈6%) or iris (≈4%). Patients initially present either with symptoms like blurred vision or photopsia, or without symptoms, with the tumour being detected in routine eye exams. Read More

View Article and Full-Text PDF
December 2021

The Effect of Intraocular Pressure-Lowering Medication on Metastatic Uveal Melanomas.

Cancers (Basel) 2021 Nov 12;13(22). Epub 2021 Nov 12.

Department of Ophthalmology, Erasmus University Medical Center, 3015 CA Rotterdam, The Netherlands.

Background: There has been speculation that IOP-lowering medication, which increases aqueous humor outflow, increases the risk of metastatic uveal melanoma (UM). This hypothesis has not been studied previously but is relevant for UM patients who use IOP-lowering medication. The aim of the current study is to assess the association between the use of intraocular pressure (IOP)-lowering medication and the risk of metastatic UM, and mortality. Read More

View Article and Full-Text PDF
November 2021

No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.

BMC Cancer 2021 Nov 24;21(1):1270. Epub 2021 Nov 24.

St. Erik Eye Hospital, Eugeniavägen 12, 17164, Stockholm, Sweden.

Objective: To assess the long-term prognosis for patients with iris melanomas and compare it with the prognosis for small choroidal melanomas.

Design: Retrospective observational case series.

Methods: All patients treated for iris melanomas at a single referral institution between January 1st 1986 and January 1st 2016 were included. Read More

View Article and Full-Text PDF
November 2021

Postradiation Optic Atrophy Is Associated With Intraocular Pressure and May Manifest With Neuroretinal Rim Thinning.

J Neuroophthalmol 2022 03 11;42(1):e159-e172. Epub 2021 Nov 11.

Departments of Ophthalmology (LAD, TWO, GWR) and Medical Physics (CLD), and Radiation Oncology (KSC, IAP), Mayo Clinic, Rochester, Minnesota.

Background: To determine risk factors for postradiation optic atrophy (PROA) after plaque radiotherapy for uveal melanoma.

Methods: A single center, retrospective cohort study of patients diagnosed with uveal melanoma involving choroid and/or ciliary body treated with plaque between January 1, 2008, and December 31, 2016. Outcomes included development of PROA with pallor alone or with concomitant neuroretinal rim thinning (NRT). Read More

View Article and Full-Text PDF

Adding the Cancer Genome Atlas Chromosome Classes to American Joint Committee on Cancer System Offers More Precise Prognostication in Uveal Melanoma.

Ophthalmology 2022 04 16;129(4):431-437. Epub 2021 Nov 16.

Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:

Purpose: Uveal melanoma (UM) is a rare disease and the most common primary intraocular malignancy in adults, with a high risk of metastases. Reliable prognostication systems are based on anatomic features, as in the tumor-node-metastasis staging of the American Joint Committee on Cancer (AJCC) system, or on genetic information, as in The Cancer Genome Atlas (TCGA) system. Prior evidence suggests that combining both systems may be beneficial. Read More

View Article and Full-Text PDF

Chromosome 3 and 8q Aberrations in Uveal Melanoma Show Greater Impact on Survival in Patients with Light Iris versus Dark Iris Color.

Ophthalmology 2022 04 13;129(4):421-430. Epub 2021 Nov 13.

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address:

Purpose: Individuals with gray, blue, or green eyes have a higher chance of developing uveal melanoma (UM) than those with brown eyes. We wondered whether iris pigmentation might be related not only to predisposition to UM but also to its behavior; therefore, we compared the clinical, histopathologic, and genetic characteristics of UM between eyes with different colors.

Design: We determined iris color in a large cohort of patients enucleated for UM. Read More

View Article and Full-Text PDF